Clinical Feasibility of the BinaxNOW™ COVID-19/Flu A&B Combo in the Southern Hemisphere

NANot yet recruitingINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

November 1, 2025

Study Completion Date

November 1, 2025

Conditions
Influenza Type AInfluenza Type BCOVID-19
Interventions
DIAGNOSTIC_TEST

BinaxNOW™ COVID-19/Flu A&B Combo Self-Test

"Diagnostic Test: BinaxNOW™ COVID-19/Flu A\&B Combo Self-Test~The BinaxNOW™ COVID-19/Flu A\&B Combo Self-Test is a visually read lateral flow in vitro immunoassay for the qualitative detection and differentiation of the nucleocapsid protein antigen to SARS-CoV-2, Influenza A, and Influenza B directly in anterior nasal swab specimens from individuals with signs and symptoms of respiratory infection."

All Listed Sponsors
lead

Abbott Rapid Dx

INDUSTRY

NCT06928129 - Clinical Feasibility of the BinaxNOW™ COVID-19/Flu A&B Combo in the Southern Hemisphere | Biotech Hunter | Biotech Hunter